Sign In
Buy SPRY
$8.75
-0.150 (-1.69%)
At Close: Jun 03, 2026
LOS ANGELES, CA / ACCESSWIRE / August 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuti
ARS Pharmaceuticals Inc. Is Being Investigated For Securities Related Impropriety And Investors Should Contact The Schall Law Firm
11:00am, Thursday, 29'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuti
The Schall Law Firm Invites Shareholders To Partake In An Inquiry Into ARS Pharmaceuticals Inc For Securities Fraud
11:00am, Wednesday, 28'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuti
LOS ANGELES, CA / ACCESSWIRE / August 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuti
Shareholders Should Reach Out To The Schall Law Firm About A Securities Fraud Inquiry Into ARS Pharmaceuticals Inc
11:00am, Monday, 26'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuti
EURneffy offers adults and children (≥30 kg) in Europe living with severe allergic reactions the first new delivery method for adrenaline in more than 30 years in the EU
LOS ANGELES, CA / ACCESSWIRE / August 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuti
A Securities Fraud Inquiry Into ARS Pharmaceuticals Inc Has Been Opened By The Schall Law Firm And Shareholders Are Invited To Join
11:00am, Saturday, 24'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuti
LOS ANGELES, CA / ACCESSWIRE / August 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuti
LOS ANGELES, CA / ACCESSWIRE / August 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuti
Earlier this month, the FDA approved ARS Pharmaceuticals Inc's SPRY neffy (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including those that are life-threaten
LOS ANGELES, CA / ACCESSWIRE / August 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuti
The Schall Law Firm Is Investigating ARS Pharmaceuticals Inc. And Investors Are Encouraged To Join
11:00am, Sunday, 18'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuti
The Schall Law Firm Is Looking Into ARS Pharmaceuticals Inc. And Harmed Investors Are Encouraged To Join
07:45pm, Thursday, 15'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuti
ARS Pharmaceuticals Inc. Is Being Investigated By The Schall Law Firm, And Affected Investors Are Urged To Engage In Dialogue
08:15pm, Wednesday, 14'th Aug 2024
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY)
